CRIS Stock Analysis: Buy, Sell, or Hold?
CRIS - Curis Inc
$0.35
-0.08 (-17.89%)
▼
5d:
+68.42%
30d:
-31.02%
90d:
-34.97%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When CRIS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRIS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CRIS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CRIS is currently trading at $0.35, which is considered oversold relative to its 30-day fair value range of $0.36 to $0.52.
Technical Outlook: Technically, CRIS is in a strong downtrend. The price is currently testing key support at $0.38. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 17.9% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.00 (+3939.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRIS is in a strong downtrend. The price is currently testing key support at $0.38. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 17.9% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.00 (+3939.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.36 -
$0.52
Company Quality Score
53/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
72.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BEARISH: Downward momentum (-17.9%)
- BULLISH: Trading 3939.2% below Wall St target ($14.00)
Trading Range Analysis
30-Day Trading Range
$0.36 -
$0.52
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.38
Resistance Level
$0.54
Current Trend
Strong Downtrend
Technical data as of
Jun 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.29
Wall Street Target
$14.00
(+3939.2%)
Revenue Growth (YoY)
-66.0%
Profit Margin
-299.7%
Share & Embed Analysis
Last updated: July 02, 2026 9:42 PM ET
Data refreshes hourly during market hours. Next update: 10:42 PM
Data refreshes hourly during market hours. Next update: 10:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRIS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 45 HOLD |
